Home | RocketVax AG

Cutting-edge
vaccine development

INTRODUCING
ROCKETVAX

a platform developing next-generation viral vaccines for emerging COVID-19 variants and other infectious diseases

Rocketvax is developing next-generation vaccines leveraging the live-attenuated virus technology in response to the extensive unmet medical need in treatment and prevention of infectious diseases.

Two of the Company’s lead candidates, sCPD9 and OTS, are targeting the vast underserved market of novel COVID-19 variants, which will allow to both manage current and emergent treatment-resistant variants and prevent the risk of yet another future pandemic, while significantly streamlining administration through needle-free nasal delivery.

20+

Novel variants
in 2024

Excellent Safety Profile

Higher efficacy

$79b

Addressable Market

THE PROBLEM

THE CHANGING
GLOBAL THREAT
OF COVID-19

44K

COVID Deaths in the US

17.8%

Peak seroprevalence rates

>80%

Of COVID cases caused by new variants

16.5

Peak hospitalization (per 100,000)

Although the impact of COVID-19 is no longer as visible as during the peak lockdown period, there is no doubt COVID-19 is here to stay, transitioning to a global endemic.

In 2024, COVID remains a public health threat and the virus continues to mutate causing periodic surges, with majority of new diagnoses caused by novel variants which cannot be effectively mitigated by currently available vaccines.

CURRENTLY AVAILABLE VACCINE OPTIONS
ALL FALL SHORT

Efficacy wanes over time, with an estimated 2x drop in effective protection from infection and death after 22 weeks.

Dominant vaccines demonstrate limited efficacy against novel variants, with long-term efficacy against Delta as low as 3%-9%.

Currently available vaccines are all injectable, which adds incision risks and creates several supply chain limitations.

THE SOLUTION

Rocketvax Platform

The Rocketvax platform develops next-generation live-attenuated virus vaccines, including a novel nasal vaccine candidate for SARS-CoV-2.

The lead candidate has demonstrated excellent results in animal studies, showcasing tremendous promise to offer superior patient outcomes for both existing and emerging COVID-19 variants.